AT502987A1 - Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen - Google Patents
Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen Download PDFInfo
- Publication number
- AT502987A1 AT502987A1 AT0206705A AT20672005A AT502987A1 AT 502987 A1 AT502987 A1 AT 502987A1 AT 0206705 A AT0206705 A AT 0206705A AT 20672005 A AT20672005 A AT 20672005A AT 502987 A1 AT502987 A1 AT 502987A1
- Authority
- AT
- Austria
- Prior art keywords
- peptide
- pro
- fibrin
- shock
- ndsk
- Prior art date
Links
- 206010049771 Shock haemorrhagic Diseases 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 238000011282 treatment Methods 0.000 title claims description 7
- 208000032456 Hemorrhagic Shock Diseases 0.000 title abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 53
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 108010073385 Fibrin Proteins 0.000 claims abstract description 15
- 102000009123 Fibrin Human genes 0.000 claims abstract description 15
- 229950003499 fibrin Drugs 0.000 claims abstract description 15
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 13
- 229940100601 interleukin-6 Drugs 0.000 claims abstract description 13
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 8
- 230000035939 shock Effects 0.000 claims abstract description 8
- 230000005764 inhibitory process Effects 0.000 claims abstract description 6
- 230000004071 biological effect Effects 0.000 claims abstract description 4
- 230000001939 inductive effect Effects 0.000 claims abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract 2
- 239000012634 fragment Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 102000008790 VE-cadherin Human genes 0.000 claims description 15
- 108010018828 cadherin 5 Proteins 0.000 claims description 15
- 230000000740 bleeding effect Effects 0.000 claims description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 2
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 2
- 208000034486 Multi-organ failure Diseases 0.000 claims description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 231100000835 liver failure Toxicity 0.000 claims description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 102000000905 Cadherin Human genes 0.000 abstract description 3
- 108050007957 Cadherin Proteins 0.000 abstract description 3
- 230000002792 vascular Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 238000005259 measurement Methods 0.000 abstract description 2
- 230000003511 endothelial effect Effects 0.000 abstract 2
- 230000001553 hepatotropic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 208000034158 bleeding Diseases 0.000 description 6
- 239000000208 fibrin degradation product Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 108010002921 NDSK-II Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 235000011483 Ribes Nutrition 0.000 description 2
- 241000220483 Ribes Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000000614 rib Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
- 101800000974 Fibrinopeptide A Proteins 0.000 description 1
- 101800003778 Fibrinopeptide B Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 229950003616 azaperone Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- -1 disulfoiodine Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- LFULEKSKNZEWOE-UHFFFAOYSA-N propanil Chemical compound CCC(=O)NC1=CC=C(Cl)C(Cl)=C1 LFULEKSKNZEWOE-UHFFFAOYSA-N 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 101150066801 tea1 gene Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0206705A AT502987A1 (de) | 2005-12-23 | 2005-12-23 | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
| EP06804388A EP1962887B1 (de) | 2005-12-23 | 2006-11-10 | Verfahren zum Bestimmen der entzündungshemmenden Wirkung eines Peptids |
| US12/158,670 US7897574B2 (en) | 2005-12-23 | 2006-11-10 | Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms |
| PCT/AT2006/000465 WO2007070899A2 (de) | 2005-12-23 | 2006-11-10 | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
| DE502006004619T DE502006004619D1 (de) | 2005-12-23 | 2006-11-10 | Verfahren zum Bestimmen der entzündungshemmenden Wirkung eines Peptids |
| RU2008130413/15A RU2008130413A (ru) | 2005-12-23 | 2006-11-10 | Фармацевтическая композиция для лечения геморрагического шока и его последствий |
| AT06804388T ATE440282T1 (de) | 2005-12-23 | 2006-11-10 | Verfahren zum bestimmen der entzündungshemmenden wirkung eines peptids |
| AU2006326890A AU2006326890A1 (en) | 2005-12-23 | 2006-11-10 | Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms |
| EP09010282A EP2110136A3 (de) | 2005-12-23 | 2006-11-10 | Pharmazeutische Zusammensetzung zur Behandlung von hämorrhagischem Schock und seinen Folgeerscheinungen |
| CNA2006800486507A CN101365477A (zh) | 2005-12-23 | 2006-11-10 | 治疗出血性休克的药物制剂及其缓释胶囊剂或缓释片剂(sequels) |
| ES06804388T ES2331970T3 (es) | 2005-12-23 | 2006-11-10 | Procedimiento para determinar el efecto antiinflamatorio de un peptido. |
| KR1020087017988A KR20080108221A (ko) | 2005-12-23 | 2006-11-10 | 출혈성 쇼크 및 그 후유증의 치료용 약제 조성물 |
| JP2008546020A JP2009520696A (ja) | 2005-12-23 | 2006-11-10 | 出血性ショックおよびその続発症を治療するための製剤 |
| CA002634026A CA2634026A1 (en) | 2005-12-23 | 2006-11-10 | Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms |
| IL192349A IL192349A0 (en) | 2005-12-23 | 2008-06-19 | Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms |
| NO20083191A NO20083191L (no) | 2005-12-23 | 2008-07-17 | Farmasoytisk sammensetning for behandling av hemoragisk sjokk og dens etterfolgende symptomer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0206705A AT502987A1 (de) | 2005-12-23 | 2005-12-23 | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT502987A1 true AT502987A1 (de) | 2007-07-15 |
Family
ID=37846035
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT0206705A AT502987A1 (de) | 2005-12-23 | 2005-12-23 | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
| AT06804388T ATE440282T1 (de) | 2005-12-23 | 2006-11-10 | Verfahren zum bestimmen der entzündungshemmenden wirkung eines peptids |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06804388T ATE440282T1 (de) | 2005-12-23 | 2006-11-10 | Verfahren zum bestimmen der entzündungshemmenden wirkung eines peptids |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7897574B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1962887B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009520696A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080108221A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101365477A (cg-RX-API-DMAC7.html) |
| AT (2) | AT502987A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006326890A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2634026A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE502006004619D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2331970T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL192349A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20083191L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2008130413A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007070899A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101389653A (zh) * | 2006-02-23 | 2009-03-18 | 菲布雷克斯医疗研究及开发有限责任公司 | 肽和肽衍生物以及含有它们的药物组合物 |
| EP2193370A2 (en) * | 2007-09-24 | 2010-06-09 | Fibrex Medical Research & Development GmbH | Methods of screening for compounds having anti-inflammatory activity |
| US20130324469A1 (en) * | 2010-12-09 | 2013-12-05 | The Brigham And Women's Hospital, Inc. | Fibrinogen and kidney damage |
| US20170112941A1 (en) * | 2015-10-13 | 2017-04-27 | Symic Ip, Llc | Ve-cadherin binding bioconjugate |
| JP7506364B2 (ja) * | 2019-10-24 | 2024-06-26 | 国立大学法人東海国立大学機構 | 慢性肺疾患／急性呼吸窮迫症候群の治療薬 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997844A (en) | 1991-02-08 | 1999-12-07 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| CA2430972C (en) | 2000-12-12 | 2014-08-05 | Fibrex Medical Research & Development Gmbh | Fibrin fragments for treating inflammation |
| US20080311103A1 (en) | 2004-03-08 | 2008-12-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Anti-Inflammatory Peptides and Methods of Use Thereof |
| AT414097B (de) | 2004-06-25 | 2006-09-15 | Petzelbauer Peter Dr | Pharmazeutische zubereitung zur behandlung von schock |
| WO2006000007A1 (de) | 2004-06-25 | 2006-01-05 | Fibrex Medical Research & Development Gesmbh | Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock |
-
2005
- 2005-12-23 AT AT0206705A patent/AT502987A1/de not_active Application Discontinuation
-
2006
- 2006-11-10 KR KR1020087017988A patent/KR20080108221A/ko not_active Ceased
- 2006-11-10 JP JP2008546020A patent/JP2009520696A/ja active Pending
- 2006-11-10 CA CA002634026A patent/CA2634026A1/en not_active Abandoned
- 2006-11-10 ES ES06804388T patent/ES2331970T3/es active Active
- 2006-11-10 AT AT06804388T patent/ATE440282T1/de active
- 2006-11-10 CN CNA2006800486507A patent/CN101365477A/zh active Pending
- 2006-11-10 AU AU2006326890A patent/AU2006326890A1/en not_active Abandoned
- 2006-11-10 EP EP06804388A patent/EP1962887B1/de active Active
- 2006-11-10 WO PCT/AT2006/000465 patent/WO2007070899A2/de not_active Ceased
- 2006-11-10 RU RU2008130413/15A patent/RU2008130413A/ru not_active Application Discontinuation
- 2006-11-10 US US12/158,670 patent/US7897574B2/en not_active Expired - Fee Related
- 2006-11-10 EP EP09010282A patent/EP2110136A3/de not_active Withdrawn
- 2006-11-10 DE DE502006004619T patent/DE502006004619D1/de active Active
-
2008
- 2008-06-19 IL IL192349A patent/IL192349A0/en unknown
- 2008-07-17 NO NO20083191A patent/NO20083191L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101365477A (zh) | 2009-02-11 |
| JP2009520696A (ja) | 2009-05-28 |
| WO2007070899A2 (de) | 2007-06-28 |
| EP2110136A2 (de) | 2009-10-21 |
| AU2006326890A1 (en) | 2007-06-28 |
| IL192349A0 (en) | 2008-12-29 |
| US7897574B2 (en) | 2011-03-01 |
| DE502006004619D1 (de) | 2009-10-01 |
| KR20080108221A (ko) | 2008-12-12 |
| EP1962887B1 (de) | 2009-08-19 |
| ATE440282T1 (de) | 2009-09-15 |
| CA2634026A1 (en) | 2007-06-28 |
| EP2110136A3 (de) | 2010-01-27 |
| RU2008130413A (ru) | 2010-01-27 |
| WO2007070899A3 (de) | 2007-10-04 |
| NO20083191L (no) | 2008-09-16 |
| ES2331970T3 (es) | 2010-01-21 |
| EP1962887A2 (de) | 2008-09-03 |
| US20090005310A1 (en) | 2009-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gardeazabal et al. | Elastin and collagen fibres in cutaneous wound healing | |
| Bishop et al. | Enhanced deposition of predominantly type I collagen in myocardial disease | |
| JP7149972B2 (ja) | シラジット（ｓｈｉｌａｊｉｔ）の使用による筋肉の増強および修復の促進と、コラーゲンおよび関係するタンパク質に関連する障害の処置 | |
| DE10234192B4 (de) | Verwendung von Erythropoetin | |
| LaBourene et al. | Alterations in elastin and collagen related to the mechanism of progressive pulmonary venous obstruction in a piglet model. A hemodynamic, ultrastructural, and biochemical study. | |
| Marsico et al. | Elastin-like hydrogel stimulates angiogenesis in a severe model of critical limb ischemia (CLI): An insight into the glyco-host response | |
| DE69007964T2 (de) | Verwendung von Thrombospondin zur Beschleunigung der Wundheilung. | |
| Viidik | Connective tissues—possible implications of the temporal changes for the aging process | |
| DE102004063927A1 (de) | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden | |
| Burgmann et al. | Increased serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease. | |
| EP1691827B1 (de) | Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock | |
| AT502987A1 (de) | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen | |
| Mizushima et al. | Effect of cardiac arrest on brain weight and the permeability of the blood-brain and blood-spinal cord barrier to albumin and tumor necrosis factor-α | |
| EP1303294B1 (de) | Verfahren zur behandlung von instabiler angina pectoris | |
| DE69836830T2 (de) | Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten | |
| Konop et al. | Kłodzi nska, E.; Sulejczak, D.; Schwartz, RA; Czuwara, J. Keratin scaffolds containing casomorphin stimulate macrophage infiltration and accelerate full-thickness cutaneous wound healing in diabetic mice | |
| US20020013359A1 (en) | Pharmaceutical composition based on proline, glycine and lysine used in the therapy for the healing of tendon lesions and open wounds | |
| AT414097B (de) | Pharmazeutische zubereitung zur behandlung von schock | |
| Lamawansa et al. | Vitamin D3 exacerbates intimal hyperplasia in balloon-injured arteries | |
| AT501263B1 (de) | Pharmazeutische zubereitung zur behandlung von schock | |
| Chello et al. | Alteration in collagen and elastin content in varicose veins | |
| XU et al. | Changes of fibronectin in the right and left ventricles of rats exposed to chronic normobaric hypoxia | |
| MX2008008324A (en) | Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms | |
| Yasuda et al. | An animal model of chronic ischemic neuropathy with proliferative changes of nerve microvessel wall | |
| LAST et al. | Particle-cell interactions: Lung fibrogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REJ | Rejection |
Effective date: 20160515 |